Cure My Disease

Don't miss your cure!

 Log in / Sign up

A phase 3, multicenter, Open-Label extension study of the Long-Term safety of ARQ-151 cream 0.3% in subjects with chronic plaque psoriasis

NCT ID NCT04286607

NEW Sponsor: Arcutis Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 09, 2026

Summary

This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

337 people

The number who actually took part.

Started

Feb 2020

Finished

Jan 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 11 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants legally competent to sign and give informed consent or informed consent of legal guardian, and, if age appropriate, assent by the subject, as required by local laws * Males and females ages 2 years and older (inclusive) * Subjects with chronic plaque psoriasis who meet eligibility criteria and: 1. Successfully completed a prior ARQ-151 cream study in psoriasis (Cohort 1) or 2. Are naïve to treatment with ARQ-151 cream (Cohort 2) * Females of childbearing potential (FOCBP) must have a negative pregnancy test at all study visits. In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial. Exclusion Criteria: * Subjects who experienced an ARQ-151 treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-151 cream in a prior ARQ-151 cream study. * Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED. * Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding. * Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator. * Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product. * Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic plaque psoriasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic plaque psoriasis

Contacts and locations

Locations

  • Arcutis Biotherapeutics Clinical Site 101

    Brighton, Massachusetts, 02135, United States

  • Arcutis Biotherapeutics Clinical Site 102

    Rolling Meadows, Illinois, 60008, United States

  • Arcutis Biotherapeutics Clinical Site 103

    London, Ontario, N6H 5L5, Canada

  • Arcutis Biotherapeutics Clinical Site 104

    College Station, Texas, 77845, United States

  • Arcutis Biotherapeutics Clinical Site 105

    Sanford, Florida, 32771, United States

  • Arcutis Biotherapeutics Clinical Site 106

    Waterloo, Ontario, N2J 1C4, Canada

  • Arcutis Biotherapeutics Clinical Site 107

    Montreal, Quebec, H3Z 2S6, Canada

  • Arcutis Biotherapeutics Clinical Site 108

    Stony Brook, New York, 11790, United States

  • Arcutis Biotherapeutics Clinical Site 109

    Peterborough, Ontario, K9J 5K2, Canada

  • Arcutis Biotherapeutics Clinical Site 110

    San Antonio, Texas, 78218, United States

  • Arcutis Biotherapeutics Clinical Site 111

    Baton Rouge, Louisiana, 70809, United States

  • Arcutis Biotherapeutics Clinical Site 112

    Fremont, California, 94538, United States

  • Arcutis Biotherapeutics Clinical Site 113

    Exton, Pennsylvania, 19003, United States

  • Arcutis Biotherapeutics Clinical Site 114

    Plainfield, Illinois, 46168, United States

  • Arcutis Biotherapeutics Clinical Site 115

    High Point, North Carolina, 27262, United States

  • Arcutis Biotherapeutics Clinical Site 116

    Clinton Township, Michigan, 48038, United States

  • Arcutis Biotherapeutics Clinical Site 117

    San Antonio, Texas, 78229, United States

  • Arcutis Biotherapeutics Clinical Site 118

    Delray Beach, Florida, 33484, United States

  • Arcutis Biotherapeutics Clinical Site 119

    Dallas, Texas, 75246, United States

  • Arcutis Biotherapeutics Clinical Site 120

    Irvine, California, 92697, United States

  • Arcutis Biotherapeutics Clinical Site 121

    New York, New York, 10029, United States

  • Arcutis Biotherapeutics Clinical Site 123

    San Diego, California, 92123, United States

  • Arcutis Biotherapeutics Clinical Site 124

    Fairborn, Ohio, 45324, United States

  • Arcutis Biotherapeutics Clinical Site 125

    Rockville, Maryland, 20850, United States

  • Arcutis Biotherapeutics Clinical Site 126

    Québec, Quebec, G1V4X7, Canada

  • Arcutis Biotherapeutics Clinical Site 127

    Encinitas, California, 92024, United States

  • Arcutis Biotherapeutics Clinical Site 128

    Duncansville, Pennsylvania, 16635, United States

  • Arcutis Biotherapeutics Clinical Site 129

    East Windsor, New Jersey, 08520, United States

  • Arcutis Biotherapeutics Clinical Site 130

    Rochester, New York, 14623, United States

  • Arcutis Biotherapeutics Clinical Site 131

    Miami, Florida, 33174, United States

  • Arcutis Biotherapeutics Clinical Site 132

    Calgary, Alberta, T1Y 0B4, Canada

  • Arcutis Biotherapeutics Clinical Site 133

    Mississauga, Ontario, L5H 1G9, Canada

  • Arcutis Biotherapeutics Clinical Site 134

    Oklahoma City, Oklahoma, 73118, United States

  • Arcutis Biotherapeutics Clinical Site 135

    Pittsburgh, Pennsylvania, 15213, United States

  • Arcutis Biotherapeutics Clinical Site 136

    San Francisco, California, 94132, United States

  • Arcutis Biotherapeutics Clinical Site 137

    Ocala, Florida, 34470, United States

  • Arcutis Biotherapeutics Clinical Site 138

    Rockville, Maryland, 20850, United States

  • Arcutis Biotherapeutics Clinical Site 139

    Reno, Nevada, 89509, United States

  • Arcutis Biotherapeutics Clinical Site 140

    Ottawa, Ontario, K2C 3N2, Canada

  • Arcutis Biotherapeutics Clinical Site 201

    North Miami Beach, Florida, 33162, United States

  • Arcutis Biotherapeutics Clinical Site 202

    Hialeah, Florida, 33016, United States

  • Arcutis Biotherapeutics Clinical Site 203

    Scottsdale, Arizona, 85255, United States

  • Arcutis Biotherapeutics Clinical Site 204

    Windsor, Ontario, N8W 1E6, Canada

  • Arcutis Biotherapeutics Clinical Site 205

    Ajax, Ontario, L1S 7K8, Canada

  • Arcutis Biotherapeutics Clinical Site 206

    Arlington, Texas, 76011, United States

  • Arcutis Biotherapeutics Clinical Site 207

    Surrey, British Columbia, V3R 6A7, Canada

  • Arcutis Biotherapeutics Clinical Site 208

    Santa Monica, California, 90404, United States

  • Arcutis Biotherapeutics Clinical Site 209

    Sweetwater, Florida, 33172, United States

  • Arcutis Biotherapeutics Clinical Site 210

    West Jordan, Utah, 84088, United States

  • Arcutis Biotherapeutics Clinical Site 211

    Lake Charles, Louisiana, 70605, United States

  • Arcutis Biotherapeutics Clinical Site 212

    Detroit, Michigan, 48202, United States

  • Arcutis Biotherapeutics Clinical Site 213

    Metairie, Louisiana, 70006, United States

  • Arcutis Biotherapeutics Clinical Site 214

    Indianapolis, Indiana, 46250, United States

  • Arcutis Biotherapeutics Clinical Site 215

    Santa Monica, California, 90503, United States

  • Arcutis Biotherapeutics Clinical Site 216

    Fridley, Minnesota, 55432, United States

  • Arcutis Biotherapeutics Clinical Site 217

    Louisville, Kentucky, 40217, United States

  • Arcutis Biotherapeutics Clinical Site 218

    Barrie, Ontario, L4M 7G1, Canada

  • Arcutis Biotherapeutics Clinical Site 219

    Las Vegas, Nevada, 89148, United States

  • Arcutis Biotherapeutics Clinical Site 220

    San Diego, California, 92123, United States

  • Arcutis Biotherapeutics Clinical Site 221

    Murfreesboro, Tennessee, 37130, United States

  • Arcutis Biotherapeutics Clinical Site 222

    Oklahoma City, Oklahoma, 73112, United States

  • Arcutis Biotherapeutics Clinical Site 223

    Boynton Beach, Florida, 91436, United States

  • Arcutis Biotherapeutics Clinical Site 224

    New Orleans, Louisiana, 70115, United States

  • Arcutis Biotherapeutics Clinical Site 225

    Encino, California, 91436, United States

  • Arcutis Biotherapeutics Clinical Site 226

    Surrey, British Columbia, V3V0C6, Canada

  • Arcutis Biotherapeutics Clinical Site 227

    Saint Joseph, Missouri, 64506, United States

  • Arcutis Biotherapeutics Clinical Site 228

    Largo, Florida, 33770, United States

  • Arcutis Biotherapeutics Clinical Site 229

    Broomall, Pennsylvania, 19008, United States

  • Arcutis Biotherapeutics Clinical Site 230

    Richmond, Virginia, 23220, United States

  • Arcutis Biotherapeutics Clinical Site 231

    Las Vegas, Nevada, 89148, United States

  • Arcutis Biotherapeutics Clinical Site 232

    Winnepeg, Manitoba, R3M 3Z4, Canada

  • Arcutis Biotherapeutics Clinical Site 233

    Knoxville, Tennessee, 37922, United States

  • Arcutis Biotherapeutics Clinical Site 234

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Arcutis Biotherapeutics Clinical Site 235

    Toronto, Ontario, M4W 2N2, Canada

  • Arcutis Biotherapeutics Clinical Site 236

    Portsmouth, New Hampshire, 03801, United States

  • Arcutis Biotherapeutics Clinical Site 237

    DeLand, Florida, 32720, United States

  • Arcutis Biotherapeutics Clinical Site 238

    Houston, Texas, 77030, United States

  • Arcutis Biotherapeutics Clinical Site 239

    Beverly Hills, California, 90212, United States

  • Arcutis Biotherapeutics Clinical Site 240

    Reno, Nevada, 89703, United States

  • Arcutis Biotherapeutics Clinical Site 508

    Los Angeles, California, 90057, United States

  • Arcutis Biotherapeutics Clinical Site 509

    Fountain Valley, California, 92708, United States

  • Arcutis Biotherapeutics Clinical Site 511

    Rancho Santa Margarita, California, 92688, United States

  • Arcutis Biotherapeutics Clinical Site 519

    Frisco, Texas, 75034, United States

  • Arcutis Clinical Site 601

    Santo Domingo, Dominican Republic

  • Arcutis Clinical Site 602

    Boise, Idaho, 83706, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.